Compare Genmab A/S (GMAB) vs Apple Inc. (AAPL) Stock

Genmab A/S (GMAB) offers the better valuation at 15.4x trailing P/E (23.2x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 15.4x versus Apple Inc. at 35.4x. On forward P/E, Genmab A/S is actually cheaper at 23.2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Genmab A/S wins at 0.80x versus Apple Inc.'s 1.74x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to -16.2% for Genmab A/S (GMAB). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus GMAB's +138.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Genmab A/S (GMAB) is the lower-risk stock at 0.61β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 109% more volatile than GMAB relative to the S&P 500. On balance sheet safety, Genmab A/S (GMAB) carries a lower debt/equity ratio of 3% versus 167% for Apple Inc. — giving it more financial flexibility in a downturn.

Genmab A/S (GMAB) is the more profitable company, earning 36.4% net margin versus 26.9% for Apple Inc. — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 31.1% for GMAB. At the gross margin level — before operating expenses — GMAB leads at 95.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Genmab A/S (GMAB) is the more undervalued stock at a PEG of 0.80x versus Apple Inc.'s 1.74x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Genmab A/S (GMAB) trades at 23.2x forward P/E versus 31.1x for Apple Inc. — 8.0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 37.6% to $40.50.

In this comparison, AAPL (0.4% yield) pays a dividend. GMAB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Genmab A/S (GMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.61), +138.4% 10Y return). Both have compounded well over 10 years (GMAB: +138.4%, AAPL: +1027%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GMAB (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. In terms of investment character: GMAB is a mid-cap deep-value stock; AAPL is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.